Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.

Future oncology (London, England)·2026
Same author

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.

Gynecologic oncology·2026
Same author

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.

Future oncology (London, England)·2025

Related Experiment Video

Updated: Jun 4, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Microarray-based gene expression studies in ovarian cancer.

Hye Sook Chon1, Johnathan M Lancaster

  • 1Department of Women's Oncology at H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, USA.

Cancer Control : Journal of the Moffitt Cancer Center
|January 29, 2011
PubMed
Summary
This summary is machine-generated.

DNA microarray technology, a genomic tool, aids in understanding ovarian cancer by profiling gene expression. This enhances knowledge of disease development, progression, and patient outcomes.

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Related Experiment Videos

Last Updated: Jun 4, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Area of Science:

  • Genomics
  • Molecular Biology
  • Oncology

Background:

  • DNA microarray technology offers a powerful approach to investigate the biological underpinnings of cancer.
  • Understanding the link between clinical cancer features and genetic alterations is crucial for advancing treatment strategies.

Purpose of the Study:

  • To review the application of genome-wide expression profiling in ovarian cancer research.
  • To highlight the role of DNA microarrays in identifying molecular markers for ovarian cancer.

Main Methods:

  • Systematic literature search of PubMed and Medline databases.
  • Inclusion of articles using keywords such as 'genome-wide', 'microarrays', 'ovarian cancer', 'prognosis', 'gene expression profiling', 'molecular marker', and 'molecular biomarker'.

Main Results:

  • Genome-wide expression profiling using DNA microarrays has significantly improved the understanding of genes involved in ovarian cancer.
  • This technology provides insights into ovarian cancer development, histopathology, progression, therapeutic response, and survival.

Conclusions:

  • Gene expression profiling is a valuable tool in ovarian cancer research.
  • Future advancements in technology, statistics, and bioinformatics are expected to enhance the reliability and clinical applicability of this technique for improved patient care.